Results of observational post-registration study of the efficacy and safety of Trekrezan® medicine use in adult patients with acute respiratory viral infection


DOI: https://dx.doi.org/10.18565/therapy.2021.8.172-181

Frolova Yu.V., Golanova N.M., Listradenkova D.G., Amon E.P., Malinnikova E.Yu.

1) Polyclinic No. 4, Smolensk; 2) Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia, Moscow
Abstract. The widespread prevalence of respiratory viruses, their genetic variability, which leads to the occurence of completely new viruses, such as SARS-CoV-2, determines the need to expand the range of drugs with both direct and indirect antiviral influence. Adaptogen with an immunomodulatory effect Trekrezan® (LLC Grotex, Russia) could be referred to such kind of medicines.
The aim of the study was to study the efficacy and safety of Trekrezan® in ARVI treatment in adults.
Material and methods. 130 patients with ARVI at the age of 18–60 years were examined. The main group included 100 patients who received Trekrezan® 200 mg according to the following scheme: on the first day – 1 tablet 3 times/day (600 mg), in the next 7 days – 1 tablet 1 time/day (200 mg). The control group included 30 patients who received symptomatic therapy, when it was necessary. The efficacy of Trekrezan® was estimated depending on the dynamics of body temperature and other clinical symptoms normalization, improvement of laboratory parameters, and the frequency of complications. Its safety was assessed by the presence or absence of adverse events, as well as the influence of the medicine on vital functions of the organism.
Results. It has been shown that the use of Trekrezan® leads to a significantly faster (on average 2,2 days) elimination of the clinical manifestations of acute respiratory viral infections due to a relieve of fever, decrease of the severity of intoxication syndrome symptoms, normalization of general clinical and biochemical blood parameters (ESR, leukocyte count and CRP) comparatively with the control group. Complications of ARVI while taking the medicine were not fixed. Adverse events in the study groups were not registered, which indicates the safety of medicine use.
Conclusion. Trekrezan® has proven its effectiveness and safety in the current study, which allows us to recommend it for ARVI treatment in adult patients.
Keywords: Trekrezan®, acute respiratory viral infections, antiviral therapy
Read entire article

Literature


  1. Основы иммунореабилитации при новой коронавирусной инфекции (COVID-19). Пособие для врачей. Под. ред. М.П. Костинова. М.: Группа МДВ. 2020; 112 с. [Fundamentals of immunorehabilitation for novel coronavirus infection (COVID-19). A guide for doctors. Ed. by Kostinov M.P. Moscow: MDV Group. 2020; 112 pp. (In Russ.)]. ISBN: 978-5-906748-06-5.

  2. Юшков В.В., Юшкова Т.А., Казьянин А.В. Иммунокорректоры: руководство для врачей и провизоров. Екатеринбург: ИРА УТК. 2002; 255 с. [Yushkov V.V., Yushkova T.A., Kazyanin A.V. Immunocorrectors: a guide for doctors and pharmacists. Ekaterinburg: IRA UTK. 2002; 255 pp. (In Russ.)].

  3. Шабанов П.Д., И.В. Зарубина, А.В. Болехан с соавт. Иммуномодулятор Трекрезан: профиль общей и иммунотропной активности. РМЖ. 2005; 20: 1361. [Shabanov P.D., I.V. Zarubina, A.V. Bolekhan et al. Immunomodulator Trekrezan: profile of general and immunotropic activity. Russkiy meditsinskiy zhurnal = Russian Medical Journal. 2005; 20: 1361 (In Russ.)].

  4. Студенцов Е.П., Рамш С.М., Казурова Н.Г. с соавт. Адаптогены и родственные группы лекарственных препаратов – 50 лет поисков. Обзоры по клинической фармакологии и лекарственной терапии. 2013; 4: 3–43. [Studentsov E.P., Ramsh S.M., Kazurova N.G. et al. Adaptogens and related groups of drugs – 50 years of searching. Obzory po klinicheskoy farmakologii i lekarstvennoy terapii = Reviews on Clinical Pharmacology and Drug Therapy. 2013; 4: 3–43 (In Russ.)]. https://dx.doi.org/ 10.17816/RCF1143-43.

  5. Максимов М.Л., Аляутдин Р.Н. Эффективность и безопасность трекрезана. Иммуномодулятор с адаптогенными свойствами. Терапия. 2017; 2: 114–121. [Maksimov M.L., Alyautdin R.N. Efficacy and safety of Trekrezan. Immunomodulator with adaptogenic properties. Terapiya = Therapy. 2017; 2: 114–121 (In Russ.)].

  6. Инструкция по медицинскому применению лекарственного препарата Трекрезан. РУ: ЛСР-008909/09 от 21.10.2020. Государственный реестр лекарственных средств Минздрава России. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=098afd66-1f12-4da2-ba54-d623c354029a&t= (дата обращения – 01.10.2021). [Instruction for the medical use of the drug Trekrezan. Registration certificate: ЛСР-008909/09 dated 21.10.2020. State Register of Medicines of the Ministry of Healthcare of Russia. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=098afd66-1f12-4da2-ba54-d623c354029a&t= (date of access – 01.10.2021) (In Russ.)].

  7. Кузнецов И.А., Смирнов А.М., Куралева О.О. с соавт. Биологические и фармакологические свойства Трекрезана. Современные проблемы науки и образования. 2015; 1–1: 1342. [Kuznetsov I.A., Smirnov A.M., Kuraleva O.O. et al. Trekrezan biological and pharmacological properties. Sovremennyye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2015; 1–1: 1342 (In Russ.)].

  8. Deme D., Telekes A. [Prognostic importance of plasma C-reactive protein (CRP) in oncology]. Orv Hetil. 2017; 158(7): 243–56. doi: 10.1556/650.2017.30646.

  9. Шульдяков А.А., Ляпина Е.П., Соболева Л.А. с соавт. Использование индукторов интерферона в клинике инфекционных болезней. Антибиотики и химиотерапия. 2018; 3–4: 28–36. [Shuldyakov A.A., Lyapina E.P., Soboleva L.A. et al. The use of interferon inducers in an infectious disease clinic. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy. 2018; 3–4: 28–36 (In Russ.)].

  10. Казимировская В.Б., Дьяков В.М., Воронков М.Г., Ковальчук С.Ф. Трекрезан: токсикология, фармакология, результаты клинических испытаний. Иркутск. 1996; 224 с. [Kazimirovskaya V.B., Dyakov V.M., Voronkov M.G., Kovalchuk S.F. Trekrezan: toxicology, pharmacology, clinical trial results. Irkutsk. 1996; 224 pp. (In Russ.)].

  11. Всемирная организация здравоохранения. Клиническое исследование препаратов для лечения COVID-19 «Solidarity». Доступ: Available at: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (дата обращения – 01.10.2021). [World Health Organization. Clinical study of drugs for the treatment of COVID-19 “Solidarity” Available at: https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (date of access – 01.10.2021) (In Russ.)].

  12. Временные методические рекомендации «Лекарственная терапия острых респираторных вирусных инфекций (ОРВИ) в амбулаторной практике в период эпидемии COVID-19» (версия 2 от 16.04.2020). Доступ: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf (дата обращения – 01.10.2021). [Temporary guidelines «Drug therapy of acute respiratory viral infections (ARVI) in outpatient practice during the COVID-19 epidemic» (version 2 of 04/16/2020). Available at: https://static-0.rosminzdrav.ru/system/attachments/attaches/000/050/033/original/RESP_REC_V2.pdf (date of access – 01.10.2021) (In Russ.)].

  13. Riley L.W. Molecular Epidemiology of infectious diseases: Principles and practices. Washington: ASM Press. 2004; 364pp. ISBN: 978-1-555-81268-3.

  14. Jin Y., Yang H., Ji W. et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12(4): E372. doi: 10.3390/v12040372.

  15. Grabowski D.C., Joynt Maddox K.E. Postacute care preparedness for COVID-19: Thinking ahead. JAMA. 2020; 323(2): 2007–2008. doi: 10.1001/jama.2020.4686.

  16. Halpin S., O’Connor R., Sivan M. Long COVID and chronic COVID syndromes. 2021; 93(3): 1242–43. doi: 10.1002/jmv.26587.


About the Autors

Yulia V. Frolova, district general physician of Polyclinic No. 4. Address: 214025, Smolensk, 37 Normandy-Neman Str. E-mail: Smolpolka4@mail.ru
Natalya M. Golanova, district general physician of Polyclinic No. 4. Address: 214025, Smolensk, 37 Normandy-Neman Str. E-mail: Smolpolka4@mail.ru
Daria G. Listradenkova, deputy chief physician for clinical expert work of Polyclinic No. 4. Address: 214025, Smolensk, 37 Normandy-Neman Str. E-mail: Smolpolka4@mail.ru
Elena. P.Amon, candidate of biological sciences, head of the educational unit of the Department of virology, Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia. Address: 125445, Moscow, 19/38 Belomorskaya Str. E-mail: virusrmapo@rambler.ru
Elena.Yu. Malinnikova, MD, head of the Department of virology, Russian Medical Academy of Continuing Professional Education of the Ministry of Healthcare of Russia. Address: Russia 125993, Moscow, 2/1 building 1 Barrikadnaya Str. E-mail: malinacgb@mail.ru. ORCID: 0000-0002-5501-5


Similar Articles

Back to Content

Бионика Медиа